CDNA - CareDx, Inc
NASDAQ
->
Healthcare
->
Diagnostics & Research
South San Francisco,
United States
Type: Equity
CDNA price evolution
CDNA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $96.37 | $93.88 | $82.78 | |
| Short term investments | $133.09 | $122.62 | $153.22 | |
| Net receivables | $66.63 | $66.16 | $60.15 | $51.06 |
| Inventory | $19.26 | $19.23 | $20.13 | $19.47 |
| Total current assets | $334.09 | $320.61 | $303.1 | $313.71 |
| Long term investments | ||||
| Property, plant & equipment | $59.84 | $61.39 | $63 | $65.14 |
| Goodwill & intangible assets | $82.23 | $83.67 | $86.04 | |
| Total noncurrent assets | $146.17 | $149.31 | $153.11 | |
| Total investments | $133.09 | $122.62 | $153.22 | |
| Total assets | $476.99 | $466.78 | $452.41 | $466.83 |
| Current liabilities | ||||
| Accounts payable | $6.24 | $5.87 | $9.98 | $12.87 |
| Deferred revenue | $1.62 | $1.35 | $2.46 | |
| Short long term debt | ||||
| Total current liabilities | $81.44 | $78.33 | $70.21 | $78.07 |
| Long term debt | $25.39 | $26.89 | $28.28 | |
| Total noncurrent liabilities | $123.78 | $125.97 | $127.43 | |
| Total debt | $25.39 | $26.89 | $28.28 | |
| Total liabilities | $203.74 | $202.11 | $196.18 | $205.5 |
| Shareholders' equity | ||||
| Retained earnings | -$704.25 | -$696.84 | -$695.45 | -$678.27 |
| Other shareholder equity | -$7.18 | -$7.96 | -$8.11 | -$6.96 |
| Total shareholder equity | $264.67 | $256.23 | $261.33 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.78 | $90.44 | $348.7 | $134.94 |
| Short term investments | $153.22 | $203.17 | $90.03 | |
| Net receivables | $51.06 | $66.31 | $59.76 | $34.62 |
| Inventory | $19.47 | $19.23 | $17.19 | $10.01 |
| Total current assets | $313.71 | $387.85 | $433.36 | $273.1 |
| Long term investments | ||||
| Property, plant & equipment | $65.14 | $70.22 | $40.04 | $25.93 |
| Goodwill & intangible assets | $86.04 | $80.57 | $87.18 | $68.21 |
| Total noncurrent assets | $153.11 | $155.14 | $133.26 | $95.41 |
| Total investments | $153.22 | $203.17 | $90.03 | |
| Total assets | $466.83 | $542.99 | $566.62 | $368.51 |
| Current liabilities | ||||
| Accounts payable | $12.87 | $9.94 | $13.34 | $9.65 |
| Deferred revenue | $2.46 | $2.42 | $5.04 | $3.56 |
| Short long term debt | ||||
| Total current liabilities | $78.07 | $75.97 | $77.3 | $69.22 |
| Long term debt | $28.28 | $33.41 | $17.39 | $16.07 |
| Total noncurrent liabilities | $127.43 | $36.1 | $23.44 | $21.61 |
| Total debt | $28.28 | $33.41 | $17.39 | $16.07 |
| Total liabilities | $205.5 | $112.08 | $100.75 | $90.83 |
| Shareholders' equity | ||||
| Retained earnings | -$678.27 | -$460.44 | -$383.19 | -$352.53 |
| Other shareholder equity | -$6.96 | -$7.5 | -$4.67 | -$2.1 |
| Total shareholder equity | $261.33 | $430.91 | $465.88 | $277.68 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $82.88 | $92.27 | $72.05 | $65.57 |
| Cost of revenue | $27.95 | $25.93 | $25.61 | |
| Gross Profit | $55.31 | $64.33 | $46.12 | $39.96 |
| Operating activities | ||||
| Research & development | $19.68 | $18.71 | $18.28 | |
| Selling, general & administrative | $48.68 | $46.74 | $46.54 | |
| Total operating expenses | $65.8 | $68.43 | $65.45 | $162.59 |
| Operating income | -$4.1 | -$19.34 | -$122.63 | |
| Income from continuing operations | ||||
| EBIT | -$4.2 | -$19.63 | -$121.09 | |
| Income tax expense | $0.2 | $0.02 | -$0.08 | $0.17 |
| Interest expense | $3 | -$2.83 | -$2.88 | -$3.16 |
| Net income | ||||
| Net income | -$7.41 | -$1.39 | -$16.66 | -$118.1 |
| Income (for common shares) | -$1.39 | -$16.66 | -$118.1 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $280.32 | $321.79 | $296.4 | $192.19 |
| Cost of revenue | $102 | $112.21 | $97.39 | $63.12 |
| Gross Profit | $178.32 | $209.58 | $199.01 | $129.08 |
| Operating activities | ||||
| Research & development | $81.87 | $90.39 | $76.53 | $48.94 |
| Selling, general & administrative | $201.2 | $196.42 | $152.21 | $102.66 |
| Total operating expenses | $381.69 | $286.81 | $228.73 | $151.6 |
| Operating income | -$203.36 | -$77.23 | -$29.73 | -$22.53 |
| Income from continuing operations | ||||
| EBIT | -$202.01 | -$80 | -$32.25 | -$20.02 |
| Income tax expense | $0.14 | $0.38 | -$1.43 | -$1.04 |
| Interest expense | -$11.87 | -$3.76 | -$0.16 | -$0.27 |
| Net income | ||||
| Net income | -$190.28 | -$76.61 | -$30.66 | -$18.71 |
| Income (for common shares) | -$190.28 | -$76.61 | -$30.66 | -$18.71 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.39 | -$16.66 | -$118.1 | |
| Operating activities | ||||
| Depreciation | $4.96 | $5.22 | $5.05 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.17 | $13.34 | $9.96 | |
| Total cash flows from operations | $18.95 | -$15.31 | -$8.38 | |
| Investing activities | ||||
| Capital expenditures | -$1.79 | -$1.49 | -$0.7 | |
| Investments | -$9.84 | $29.15 | $42.96 | |
| Total cash flows from investing | $1.63 | -$11.63 | $27.66 | $41.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.12 | $0.02 | -$25.96 | |
| Net borrowings | ||||
| Total cash flows from financing | -$4.7 | -$4.85 | -$1.27 | -$26.88 |
| Effect of exchange rate | $0.13 | $0.01 | $0.03 | $0.11 |
| Change in cash and equivalents | $13.21 | $2.49 | $11.1 | $6.22 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$190.28 | -$76.61 | -$30.66 | -$18.71 |
| Operating activities | ||||
| Depreciation | $19.82 | $16.01 | $11.88 | $9.54 |
| Business acquisitions & disposals | -$6.68 | -$0.61 | -$15.43 | |
| Stock-based compensation | $49.09 | $46.55 | $36.08 | $23.4 |
| Total cash flows from operations | -$18.39 | -$25.24 | -$19.29 | $33.43 |
| Investing activities | ||||
| Capital expenditures | -$8.34 | -$21.23 | -$13.56 | -$7.11 |
| Investments | $56.37 | -$203.56 | $83.41 | -$90.03 |
| Total cash flows from investing | $40.45 | -$228.5 | $47.71 | -$100.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$25.92 | $4.02 | $203.77 | $167.86 |
| Net borrowings | -$0.07 | -$0.18 | ||
| Total cash flows from financing | -$29.61 | -$4.54 | $185.64 | $163.15 |
| Effect of exchange rate | -$0.11 | $0.02 | -$0.3 | $0.27 |
| Change in cash and equivalents | -$7.66 | -$258.25 | $213.76 | $96.46 |
News
Fundamentals
| Market cap | $1.06B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 53.11M |
| Revenue | $312.77M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$143.56M |
| Revenue Q/Q | 23.35% |
| Revenue Y/Y | 5.26% |
| P/E ratio | -7.41 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 3.40 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.70 |
|---|---|
| ROA | -30.82% |
| ROE | N/A |
| Debt/Equity | 0.79 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.10 |
| Quick ratio | 3.87 |